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EXTending Life
by Julie O’Connor

S

lowing the aging process, delaying the onset of diseases,
extending cellular life… as people grow older, they often

seek products or therapies to try to stay young and healthy. A

W

may have discovered the proverbial “fountain of youth” that
may one day help us all to live better and happier lives.
Stanley R. Terlecky, Ph.D., associate professor of pharmacology
in the School of Medicine has identified a novel technology
that can reduce or even eliminate accumulation of free radicals
or oxidants in cells long associated with the aging process. His
research focuses on peroxisomes, essential subcellular structures
whose critical roles in metabolism, aging, and disease have only

“We are currently examining whether or
not our biologic can be aerolized in a
form which permits delivery to the lung
as a potential treatment for this devastating class of pulmonary disease.”

— Dr. Stanley Terlecky

recently come to light.
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The technology
As we age, our cells undergo an irreversible physiological
decline caused by a variety of factors including shortening

To neutralize its toxic effects, peroxisomes pull the antioxidant

of chromosome ends, DNA damage and the accumulation of

enzyme catalase from the cytosol of the cell – the “soup” within

harmful oxygen species. Peroxisomes are at the center of this

which all the other cell organelles reside. A healthy peroxisome

process to an extent never before appreciated. They not only

will then use the imported catalase to convert potentially

carry out critical cellular functions but also produce potentially

dangerous hydrogen peroxide to harmless water and oxygen.

toxic metabolites as the “spent fuel” from these reactions.

This process can be thrown off kilter however, as cells age or

Hydrogen peroxide is one of these harmful byproducts generated

are affected by disease or mutation. The result is that catalase

by peroxisomes that can be deadly to cells.
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“We are currently examining whether or not our
biologic can be aerolized in a form which permits
delivery to the lung as a potential treatment for this
devastating class of pulmonary disease,” added

“Through all of this, I have
learned that it takes time to develop a marketable compound.”

— Dr. Stanley Terlecky

Dr. Terlecky.
Dr. Terlecky and a team of researchers also are
looking at other potential uses for their technology
including treatment of a number of skin diseases
such as psoriasis and dermatitis, as well as treating
and protecting surrounding skin tissue exposed or
damaged by radiation or photodynamic therapies.
“We are also looking at CATSKL™ as a preservation
solution,” Dr. Terlecky said. In heart, lung,
liver, and kidney transplants, the cessation and
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subsequent commencement of blood flow causes
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Mr. John Tesija, vice president and head of operations,
EXT Life Sciences, Inc

is not properly utilized by peroxisomes, with dire
consequences to the cell and the entire organism.
“By doing focused research on the peroxisome,
we discovered it is a viable, druggable target,” said
Dr. Terlecky. “Unlike mitochondria, to which you
can’t deliver a protein directly, peroxisomes are
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mechanistically much different.” Dr. Terlecky and

reperfusion injury that result in inflammation and

fellow expert in cellular trafficking pathways, Paul

oxidative damage to the organ. “CATSKL™ may be

A. Walton, Ph.D., from the University of Western

able to thwart this from occurring in the transplant

Ontario, created a novel protein therapeutic that

process,” he said.

can be delivered into a human cell and then sent to

In addition to the many pharmaceutical uses,

the peroxisome to neutralize harmful oxidants. This

CATSKL™ has tremendous potential as an “active”

proprietary technology is called CATSKL™.

component of so-called cosmeceutical products.

“The compound has great potential for treating

It can be formulated with a number of other

serious health problems including ischemia-

ingredients as an effective antioxidant in various

reperfusion injury associated with heart attack

skincare products.

or stroke, inflammation and related arthritic
conditions, and type 2 diabetes, among others,”
Terlecky commented. In addition, idiopathic
pulmonary fibrosis kills 40,000 people per year and

Bringing CATSKL™ to life
– EXT Life Sciences, Inc.
In 2004, Dr. Terlecky and his friend, John Tesija,

there are no cures or effective treatments. There is

were having a discussion about this discovery. What

evidence the pathology is associated with excessive

was meant to be a casual conversation turned into

production of reactive oxygen species (i.e. oxidants).

a partnership that brought EXT Life Sciences, Inc.,
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working with development partners to bring their
first product to market.
“We are currently partnering with carefully
selected companies to develop the product, with
the goal of bringing an over-the-counter skin care
product to market in 2009,” said Dr. Terlecky.
The product will be marketed as a novel targeted
antioxidant in a formulation specifically designed to
prevent collagen breakdown and reduce skin aging.
“Through all of this, I have learned that it takes
time to develop a marketable compound,” said Dr.
Terlecky. He welcomes the process adding, “Our
research truly bridges the translational gap – having
been developed in the laboratory but ultimately
being of benefit in the clinic.” Through his
important research, Dr. Terlecky may one day find
systemic pathologies, ultimately helping many in
their fight against disease.

About Dr. Stanley Terlecky:

Dr. Terlecky received his

B.A. in the history of art from New York University and his Ph.D.
Dr. Stanley Terlecky, associate professor of Pharmacology
and co-founder, EXT Life Sciences, Inc.

to fruition. With Terlecky’s scientific expertise and
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potential treatments or cures for numerous skin and
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in cellular and molecular physiology from Tufts University. He
joined Wayne State University in 1998 after completing an
NIH-sponsored postdoctoral fellowship in the Department of
Biology at the University of California, San Diego.

Tesija’s legal and business savvy, the two became
partners, along with Gary Novara. Tesija and Novara
are the principle partners of Southfield’s Novara and
Tesija, P.L.L.C., a law firm with expertise in pension
and corporate law. Today, EXT Life Sciences, Inc. is
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